Part3: Untreated CLL
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies (NCT03198650) | AstraZeneca | 2017-06-27 |
Track Part3: Untreated CLL automatically
Every clearance here is in the API, with alerts when new ones post.